



Funded by  
the European Union



Harmonis@tion



EUROPEAN COOPERATION  
IN SCIENCE & TECHNOLOGY

# The Joint 23<sup>rd</sup> ENS@T and 3<sup>rd</sup> Cost Harmonis@tion Meeting

## “Fighting Adrenal Tumors Together”

October 2<sup>nd</sup>-4<sup>th</sup>, 2024, Palma de Mallorca, Spain

Venue: Auditorium de Palma de Mallorca

Av. de Gabriel Roca, 18, Ponent, 07014

### Oral Presentation Guidelines:

- **Presentation Length:** Each presentation should be 7 minutes long (maximum), followed by 4 minutes for Q&A.
- **Schedule Information:** The presentation number (OR1 to OR43) and the day/time of each presentation are available in the online meeting program.
- **File Naming:** Name your presentation file using the format: OR#\_name.surname (e.g., OR1\_Charles.Darwin).
- **File Submission:** Handle your PowerPoint or PDF file at the Technical Desk on Wednesday, Oct 2<sup>nd</sup>, between 12:00h and 13:30h.

### Guided Posters (GP) and Posters (P) Presentation Guidelines:

- **Size:** The posters should be printed in a vertical format. The maximum allowed dimensions are 1 meter in width and 2 meters in height. Please feel free to choose the size that works best for you within these limits. Posters printed in smaller sizes will fit perfectly well! The organizers will provide materials for hanging the posters.
- **Number:** GP and P numbers are available in the online meeting program.
- **Presentation Schedule:**

#### **Guided Posters GP1 - GP36 & Posters P37 - P70:**

- These posters should be hung in their designated slots on Wednesday, Oct 2<sup>nd</sup>. The suggested time for installation is right after registration, between 12:00h and 13:30h
- They will be presented during their scheduled times on Thursday, Oct 3<sup>rd</sup>
- These posters must be taken down on Thursday between 19:45h and 19:50h.

#### **Posters P71 - P137:**

- These posters should be hung in their designated slots on Thursday, Oct 3<sup>rd</sup>, from 19:50h to 20:00h
- They will be presented on the morning of Friday, Oct 4<sup>th</sup>



Funded by  
the European Union



Harmonis@tion



EUROPEAN COOPERATION  
IN SCIENCE & TECHNOLOGY

# The Joint 23<sup>rd</sup> ENS@T and 3<sup>rd</sup> Cost Harmonis@tion Meeting

## “Fighting Adrenal Tumors Together”

### Meeting Program

---

Wednesday, October 2<sup>nd</sup>

---

#### Cost Harmonis@tion Adrenal Tumour Masterclass

Chairs: *Martin Fassnacht* and *Mercedes Robledo*

- 12:00-13:30** - On-site Check-in & Coffee  
- Handling of Files for Oral Presentations at the "Technical Desk"  
- Installation of Guided Posters GP1-GP36 & Posters P37-P70  
These posters can be installed at any time throughout the day. Additional information about poster is provided below.
- 13:45-14:00** Welcome Address  
[Rodrigo Toledo](#), [Darko Kastelan](#), [Guillaume Assié](#)
- 14:00-14:30** “How AI can improve management of cancer patients”  
[Bastien Rance](#)
- 14:30-15:00** “Are microRNAs helpful to predict metastases in ACC and PPGL?”  
[Peter Igaz](#)
- 15:00-15:30** “Kids with ACC/PPGL are not just little adult patients - difference between paediatric and adult disease”  
[Verena Wiegering](#)
- 15:30-16:00** “Innovative clinical trial design in rare tumours”  
[Jaume Capdevila](#)
- 16:00-16:15** Clinical PPGL case  
[Julien Riancho](#)



Funded by  
the European Union



Harmonis@tion



EUROPEAN COOPERATION  
IN SCIENCE & TECHNOLOGY

- 16:15-16:30** Clinical ACC case  
**Anja Barac Nekić**
- 16:30-16:45** Clinical APA case  
**Marcus Quinkler**
- 16:45-17:00** Clinical NAPACA case  
**Anna Angelousi**
- 17:00-17:15** Pheipas (PPGL/ACC patients association), Paradifference Foundation (metastatic PPGL), Nefkens Adrenal Cancer Foundation, Let's cure ACC
- 17:15-17:35** Coffee Break
- 17:35-18:20** Harmonis@tion WG1-2 meeting: Harmonizing clinical practice for adrenal tumours
- 18:20-19:05** Harmonis@tion WG3-4 meeting: Harmonizing Information Technology (IT)/Artificial Intelligence (AI) tools towards a standardized registry
- 19:05-19:30** "How to best share clinical data?"  
**Anthony Stell**
- 19:30-20:00** Harmonis@tion WG5 meeting: Communication, dissemination, and inclusiveness.
- 20:00-22:30** Welcome Reception and Dinner at the Venue (Palma Auditorium)

---

## Thursday 3rd October 2024

---

- 08:00-09:00** Harmonis@tion Management Committee Meeting (**only for the Committee**)

### ENS@T/Harmonis@tion Meeting

- 09:00-09:05** Welcome Address and Practical Information
- 09:05-09:45** ENSAT General Assembly
- 09:45-10:15** ENSAT Database 1/2



- 10:15-12:15 Oral Communications (ACC) – Chairs: Massimo Terzolo, Marta Araujo**
- 10:15-10:26 OR1:** Single-nucleus atlas of adrenocortical carcinoma (ACC) reveals tumor ecotypes associated with outcome (*Anne Jouinot*)
- 10:26-10:37 OR2:** Glucocorticoid excess drives receptor tyrosine kinase ROR1 expression and efficacy of glucocorticoid resistant ROR1 CAR-T cells in advanced adrenocortical carcinoma (*Marc Philipp Schauer*)
- 10:37-10:48 OR3:** Gene expression patterns can predict response to mitotane treatment in adrenocortical carcinoma; the first step towards a personalized treatment approach (*Charlotte Vietor*)
- 10:48-10:59 OR4:** AI-guided identification of risk variants for adrenocortical tumors in p.R337H TP53 carrier children (*Enzo Lalli*)
- 10:59-11:10 OR5:** Ablation of Znr3 & Trp53 induces metastatic adrenocortical carcinoma in mice (*Diana Garcia-Garcia*)
- 11:10-11:21 OR6:** Mitotane treatment of adrenocortical carcinoma induces Growth differentiation factor 15 (GDF-15) secretion and is associated with poor prognosis and impaired responsiveness to immunotherapy (*Isabel Weigand*)
- 11:21-11:32 OR7:** Does the national ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France? (*Rossella Libe*)
- 11:32-11:43 OR8:** Outcome of patients with adrenocortical carcinoma (ACC) with rare histological subtypes - an ENS@T study (*Otilia Kimpel*)
- 11:43-11:54 OR9:** Advances in T cell-based immunotherapeutic approaches for adrenocortical carcinoma (*Laura-Sophie Landwehr*)
- 11:54-12:05 OR10:** Serum metabolomics reveals widespread metabolic dysregulation in adrenocortical carcinoma (*Vasileios Chortis*)
- 12:05-12:16 OR11:** Impact of Environmental Pollution on Adrenocortical Carcinoma in Italy (*Soraya Puglisi*)
- 12:16-13.15 Lunch**
- 13:15-15:00 Oral Communications (ACC/PPGL) – Chairs: Guillaume Assié (ACC), Elena Rapizzi (PPGL)**
- 13:15-13:26 OR12:** ACCacia, a novel machine-learning approach for adrenocortical carcinomas molecular classification in routine care (*Victor Gravrand*)
- 13:26-13:37 OR13:** Cellular landscape of adrenocortical carcinoma at single-nuclei resolution (*David Tourigny*)
- 13:37-13:48 OR14:** Adrenal Cortical Organoids as Disease Models and Patient Avatars (*Jelte Yoran van der Vaart*)
- 13:48-13:59 OR15:** Clinical Predictors of Treatment Response in Advanced Adrenocortical Carcinoma: A Multicentre ENSAT Study (*Alessandra Mangone*)



Funded by  
the European Union



Harmonis@tion



EUROPEAN COOPERATION  
IN SCIENCE & TECHNOLOGY

- 13:59-14:10** **OR16:** Plasma circulating tumor DNA as a prognostic biomarker in metastatic pheochromocytoma and paraganglioma (mPPGL) (*Carlota Arenillas*)
- 14:10-14:21** **OR17:** Facilitated decision-making for screening patients with suspected pheochromocytoma and paraganglioma: a machine learning modeling cross sectional study (*Christina Pamporaki*)
- 14:21-14:32** **OR18:** Copy-number phylogenies in primary-metastases paired samples from mPPGL patients: the missing piece (*Ester Arroba*)
- 14:32-14:43** **OR19:** Anti-angiogenic Therapy in the First Patient-derived Xenograft Model of Pheochromocytoma (*Hermine Mohr*)
- 14:43-14:54** **OR20:** 2023 SDH Genotype-Phenotype Study (*Jean-Pierre Bayley*)
- 15:00-16:00** **Coffee Break & Poster Guided Tour ACC/PPGL** – Chairs: *Barbara Altieri* (ACC), *María Calatayud* (PPGL)
- 16:00-17:50** **Oral Communications (PPGL)** – Chairs: *Judith Favier*, *Maribel del Olmo*
- 16:00-16:11** **OR21:** Combinatorial therapeutic targeting of PI3K and CDK4/6 displays synergistic antitumor effects in pheochromocytoma (*Bhargavi Karna*)
- 16:11-16:22** **OR22:** International consensus statement on the diagnosis and management of pheochromocytoma and paraganglioma in children and adolescents (*Ruth Casey*)
- 16:22-16:33** **OR23:** Benefits of medical therapy with alpha-adrenergic inhibition pre-operatively for secretory paragangliomas – more than just blood pressure control (*Nicola Tufton*)
- 16:33-16:44** **OR24:** The impact of sex hormones on pheochromocytomas and paragangliomas (*Katharina Wang*)
- 16:44-16:55** **OR25:** Clinical Diagnosis and Management of Pheochromocytoma and Paraganglioma in Children and Young People (CYP): A National Guideline - on Behalf of the UK Paediatric Pheochromocytoma and Paraganglioma Guideline Development Group (*Prateek Yadav*)
- 16:55-17:06** **OR26:** Sex-dependent differences in catecholamine secretion machinery in pheochromocytomas and paragangliomas (*Nicole Bechmann*)
- 17:06-17:17** **OR27:** Circulating markers of inflammation in patients with pheochromocytoma and paraganglioma (*Margo Dona*)
- 17:17-17:28** **OR28:** Development and validation of a clinico-pathological model to early detect cluster 1 mutations in patients with pheochromocytoma and paraganglioma (*Mirko Parasiliti-Caprino*)
- 17:28-17:39** **OR29:** Clinical characteristics and management of FH-related pheochromocytomas and paragangliomas: what we learned from a large Italian kindred and the literature review (*Andrea Contarino*)



Funded by  
the European Union



Harmonis@tion



EUROPEAN COOPERATION  
IN SCIENCE & TECHNOLOGY

- 17:39-17:50** **OR30:** Cardiovascular and metabolic phenotypes of patients with pheochromocytoma and paraganglioma (*Alessia Pinna*)
- 17:50-18:45** **Coffee Break & Poster Guided Tour** **APA/NAPACA** – Chairs: *Sheerazed Boulkroun* (APA), *Felicia Hanzu* (NAPACA)
- 18:45-19:45** **ENS@T KIDS/APA/NAPACA WG meeting**
- 19:45-19:50** **Removal of Guided Posters GP1-GP36 & Posters P37-P70**
- 19:50-20:00** **Installation of Posters P71-P137**
- 20:15-23:30** **Dinner & ENS@T Best Scientific Paper Awards**
- 

## Friday 4th October 2024

---

- 08:00-08:30** **ENS@T Database 2/2**
- 08:30-10:55** **Oral Communications (APA/NAPACA)** - Chairs: *Cristina Ronchi*, *Marcus Quinker*
- 08:30-08:41** **OR31:** A Newly Developed Severity Classification and its Strategic Application in the Clinical Practice of Primary Aldosteronism (*Masanori Murakami*)
- 08:41-08:52** **OR32:** New cell and animal models to decipher the molecular mechanisms of primary aldosteronism (*Sheerazed Boulkroun*)
- 08:52-09:03** **OR33:** NTpro-BNP levels in patients with primary hyperaldosteronism and autonomous cortisol co-secretion (*Anna Hirsch*)
- 09:03-09:14** **OR34:** Preclinical *in vitro* characterization of CYP11B2 inhibitors by continuous flow-through cell culture – impacts on steroidogenesis enzyme kinetics (*Dennis Fröbel*)
- 09:14-09:25** **OR35:** Short-Term Effect on Tissue Sodium Distribution in Hypertensive Patients Following Sodium Loading Test: a Sodium MRI study (*Sven Gruber*)
- 09:25-09:36** **OR36:** Incident changes of the 1mg-overnight dexamethasone suppression test correlate with mortality and other long-term clinical outcomes in patients with adrenal incidentalomas: results from the multi-centre DEX-AI and CORTEX-AI ENSAT studies (*Onnicha Suntornlohanakul*)
- 09:36-09:47** **OR37:** Long-Term Cardiovascular Outcomes in Patients with Bilateral Adrenal Cortisol Secreting Tumors Depending on Different Treatment Approaches (*Elisabeth Nowak*)
- 09:47-09:58** **OR38:** Light chromatography and mass spectrometry proteomic analysis of formalin fixed tissue of Bilateral Macronodular Adrenocortical Disease (BMAD) (*Florian Violon*)



- 09:58-10:09** **OR39:** Surgical Versus Conservative Management for MACS: the CHIRACIC prospective randomized trial (*Antonie Tabarin*)
- 10:09-10:20** **OR40:** Carney complex patients carrying the c.709-7\_709-2del PRKAR1A pathogenic variant or a PRKACA constitutive duplication present mostly an adrenal restricted phenotype with Cushing syndrome due to Primary Pigmented Nodular Adrenal Disease (PPNAD) (*Patricia Vaduva*)
- 10:20-10:31** **OR41:** Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias – the prospective cross-sectional diagnostic test accuracy study FAMIAN (*Stefanie Hahner*)
- 10:31-10:42** **OR42:** Macrophage polarisation in patients with autonomous cortisol excess (*Ana Crastin*)
- 10:42-10:53** **OR43:** Prediction of adrenal mass nature through radiomics and deep learning: preliminary results from the ENS@T RADIO-AI multicentric study (*Lorenzo Tucci*)
- 10:55-11:35** **Coffee Break & Poster Session**
- 11:35-12:35** **ACC/PPGL WG meeting**
- 12:45-12:50** **Awards for Best Oral Presentation & Best Poster**
- 12:50-13:20** **Future ENS@T meetings**
- 13:20-13:30** **Meeting Closing**

---

## POSTERS

---

### Guided Posters (GP) - Thursday, 3<sup>rd</sup> October 2024

---

**Topic: ACC**

Date	ID	Abstract Title	Author
Oct 3rd	<b>GP1-ACC</b>	Cell cycle checkpoint inhibition potentially enhances CAR-T cell efficacy in adrenocortical carcinoma	Schauer Marc Philipp
Oct 3rd	<b>GP2-ACC</b>	Glucocorticoid-dependent metabolic rewiring enhances B7-H3 expression and efficacy of dual targeting logic gate CAR-T cells in adrenocortical carcinoma	Schauer Marc Philipp
Oct 3rd	<b>GP3-ACC</b>	Activity and safety of cisplatin plus nivolumab in advanced adrenocortical carcinoma patients	Rodella Sara
Oct 3rd	<b>GP4-ACC</b>	Adrenocortical tumor cells induce M2-like polarization of human monocytes through alternative secretion of prostaglandin E2 (PGE2) and glucocorticoids	Triebig Alexandra



Oct 3rd	GP5-ACC	Wnt/ $\beta$ -Catenin pathway activation is not associated with immune cell infiltration or steroid phenotype in adrenocortical carcinoma (ACC)	Maier Tanja
Oct 3rd	GP6-ACC	Risk factors for venous thromboembolism in adrenocortical carcinoma patients: a multicentre retrospective evaluation	Trevisan Benedetta
Oct 3rd	GP7-ACC	Understanding the role of the immune microenvironment in adrenocortical carcinoma tumor progression: first step towards development of effective immunotherapy?	Voisin Allison
Oct 3rd	GP8-ACC	Effect of Progesterone on 2D and 3D Experimental Cell Models of Adrenocortical Carcinoma Treated with EDP-M scheme.	Tamburello Mariangela
Oct 3rd	GP9-ACC	Testosterone and its downstream effectors in anti-tumour response in ACC	Garcia-Garcia Diana

**Topic: PPGL**

Date	ID	Abstract Title	Author
Oct 3rd	GP10-PPGL	An investigation into a potential novel predisposing mutation leading to dysregulated mitochondrial metabolism in hereditary paraganglioma and pheochromocytoma	Westbrook Rebecca
Oct 3rd	GP11-PPGL	Canine pheochromocytoma organoids: an <i>in vitro</i> animal model	Galac Sara
Oct 3rd	GP12-PPGL	Unveiling the Role of Horizontal Mitochondria Transfer in SDH-Deficient Paraganglioma and Pheochromocytoma Tumorigenesis	San-Juan-Guardado Jaime
Oct 3rd	GP13-PPGL	FH gene mutations and cancer predisposition: elucidating the specific tumorigenesis mechanisms associated with hereditary paraganglioma	Cajamarca Ocampo Sara
Oct 3rd	GP14-PPGL	Role of the kynurenine pathway in PPGL treatment strategies	Zygiene Gintare
Oct 3rd	GP15-PPGL	Study of the therapeutic potential of dimethylfumarate in SDH-deficient paragangliomas and pheochromocytomas: Induction of ferroptosis and clinical implications	Jacquet Amandine
Oct 3rd	GP16-PPGL	Advancing Cellular Models and Understanding Molecular Pathogenesis in Paraganglioma and Pheochromocytoma Research	Cubiella Tamara
Oct 3rd	GP17-PPGL	Characterization of paraneoplastic inflammatory anemias associated with metastatic pheochromocytomas or paragangliomas	Moog Sophie
Oct 3rd	GP18-PPGL	Multi-omic characterisation of SDHx and FH knockout cell lines to identify novel molecular mechanisms contributing to phaeochromocytoma and paraganglioma (PPGL)	Salsbury Grace

**Topic: APA**

Date	ID	Abstract Title	Author
Oct 3rd	GP19-APA	Improved selectivity of adrenal venous sampling with the use of alternative steroids to cortisol	Alessi Francesco
Oct 3rd	GP20-APA	Role of the mineralocorticoid receptor in the physiology of the adrenal cortex and the development of aldosterone producing adenomas	Fayad May





Oct 3rd	<b>GP21-APA</b>	Influence of smoking on cardiometabolic profile and surgical outcomes in patients with primary aldosteronism. A series of 881 cases.	Araujo-Castro Marta
Oct 3rd	<b>GP22-APA</b>	Impact of cortisol-cosecretion on adrenal venous sampling results in primary aldosteronism. Study of 225 cases.	Lamas Cristina
Oct 3rd	<b>GP23-APA</b>	Update on the utility of circulating miRNA and deep learning for differentiating uni- and bilateral primary aldosteronism	Vekony Balint
Oct 3rd	<b>GP24-APA</b>	Phenotype and outcome of patients with primary aldosteronism and primary bilateral macronodular adrenocortical hyperplasia: a multicenter retrospective study.	Panarelli Annalisa
Oct 3rd	<b>GP25-APA</b>	KASAI score as a predictive tool for the primary aldosteronism subtyping	Pierman Guillaume
Oct 3rd	<b>GP26-APA</b>	Prevalence of metabolic-associated fatty liver disease in patients with primary aldosteronism	Tizianel Irene
Oct 3rd	<b>GP27-APA</b>	Sexually Dimorphic Changes in Adrenocortical Cell Transdifferentiation and Activation of Signalling Pathways in Response to Pathophysiological Stimuli	Faedda Nicolò

**Topic: NAPACA**

Date	ID	Abstract Title	Author
Oct 3rd	<b>GP28-NAPACA</b>	Natural history of bilateral adrenal incidentalomas: a large monocentric cohort study	Palmieri Serena
Oct 3rd	<b>GP29-NAPACA</b>	Fragility fractures are associated with cortisol secretion in patients with nonfunctioning adrenal incidentalomas	Favero Vittoria
Oct 3rd	<b>GP30-NAPACA</b>	Long-term follow-up of familial BMAD with ARMC5 pathogenic variants	Charchar Helaine L.
Oct 3rd	<b>GP31-NAPACA</b>	Single-Nucleus RNA Sequencing Reveals The Impact of High-Fat Diet on Mouse Adrenal Gland.	Murakami Masanori
Oct 3rd	<b>GP32-NAPACA</b>	Role of ccfDNA-based biomarkers in classification of adrenocortical adenomas	Tourigny David S
Oct 3rd	<b>GP33-NAPACA</b>	Reconstitution of human adrenal gland development using pluripotent stem cells	Sasaki Kotaro
Oct 3rd	<b>GP34-NAPACA</b>	Associated malignant tumors in patients with Nonfunctioning Adrenal Incidentaloma	Campioni Lorenzo
Oct 3rd	<b>GP35-NAPACA</b>	Dysregulation of salivary cortisol rhythm in non-secreting and mild cortisol-secreting adrenal incidentalomas	Coscia Kimberly
Oct 3rd	<b>GP36-NAPACA</b>	Correlation Between Basal ACTH and Number of ACTH Receptor Immunoreactive Cells in Adrenal Adenomas	Danielsson Malin

**Poster (P) Presentation - Thursday, 3<sup>rd</sup> October 2024**

Date	ID	Abstract Title	Author
Oct 3rd	<b>P37-ACC</b>	Sphingosine kinase 1 inhibitor safinol as a new possible therapeutic strategy for adrenocortical carcinoma	Nozza Emma
Oct 3rd	<b>P38-ACC</b>	Circulating micro-RNAs are valuable biomarkers for the diagnosis and surveillance of adrenocortical tumors.	Mytareli Chrysoula
Oct 3rd	<b>P39-ACC</b>	A Snapshot of Adrenocortical Carcinoma in Spain: Insights from the Icarus Registry	Hanzu Felicia



Oct 3rd	<b>P40-ACC</b>	Assessing Human Monocyte Migration and Co-Culture with Adrenocortical Cancer Cells	Hong Cong
Oct 3rd	<b>P41-ACC</b>	Clinical and pathological characteristics of children with adrenocortical tumors: Hacettepe experience with 54 cases	Yalçın Bilgehan
Oct 3rd	<b>P42-ACC</b>	Prognostic role of pretreatment 18F-FDG PET/CT in patients affected by adrenocortical carcinoma and treated with chemotherapy.	Bettini Davide Lorenzo
Oct 3rd	<b>P43-ACC</b>	Mitotane effect on Wnt pathways and cytokines secretion in ACC spheroids	Abate Andrea
Oct 3rd	<b>P44-ACC</b>	Treatment-related adverse events associated to mitotane in patients with adrenocortical carcinoma: a multicenter ENSAT study.	Altieri Barbara
Oct 3rd	<b>P45-PPGL</b>	Dashboard Visualization of the Trajectory of Patients with Metastatic Pheochromocytoma and Paraganglioma for Precision Medicine	Uchihara Masaki
Oct 3rd	<b>P46-PPGL</b>	Safety of Biopsy in Pheochromocytoma/paraganglioma	Zhang Liang
Oct 3rd	<b>P47-PPGL</b>	Clinical and molecular analysis of paragangliomas - a single tertiary center experience	Opalińska Marta
Oct 3rd	<b>P48-PPGL</b>	Chromogranins and derived peptides in biochemical diagnosis of adrenal incidentalomas and catecholamine-producing tumors	Glinicki Piotr
Oct 3rd	<b>P49-PPGL</b>	Efficacy of RET inhibitors in the management of advanced, RET mutated pheochromocytoma. Review of published cases with the addition of 2 new cases.	Cremaschi Valentina
Oct 3rd	<b>P50-PPGL</b>	The Founder effect in PPGLs-behind the genetic clusters classification	Lider Burciulescu Sofia Maria
Oct 3rd	<b>P51-PPGL</b>	Deciphering mechanisms of metastasis in paragangliomas and pheochromocytomas: Insights from SDHB-deficient tumors through epigenetic and proteomic analyses	Chiara María-Dolores
Oct 3rd	<b>P52-PPGL</b>	Metastatic paragangliomas – real world data in a single tertiary center.	Thanasoula Foteini
Oct 3rd	<b>P53-APA</b>	Serum MicroRNA as peripheral markers in primary aldosteronism.	Makhnov Nikita
Oct 3rd	<b>P54-APA</b>	The Association between Primary Aldosteronism and Primary Hyperparathyroidism: Two Case Reports	Risio Alessandro
Oct 3rd	<b>P55-APA</b>	The effect of adrenalectomy on metabolic parameters in patients with primary aldosteronism	Đukić Mirjana
Oct 3rd	<b>P56-APA</b>	The usefulness of left adrenal vein sampling in classifying primary hyperaldosteronism subtypes	Koukoulou Chrysoula
Oct 3rd	<b>P57-APA</b>	Evaluation of two confirmatory tests for the diagnosis of primary aldosteronism	Matrozova Joanna
Oct 3rd	<b>P58-APA</b>	Prevalence and Main Characteristics of Primary Aldosteronism in PBMAH: A Systematic Review of the Literature	Panarelli Annalisa
Oct 3rd	<b>P59-APA</b>	Systemic inflammatory burden in primary hyperaldosteronism: a systematic review and results of original data	Mori Ubaldini Giulia
Oct 3rd	<b>P60-APA</b>	An attempt for a new screening test to predict the response to saline infusion test in primary aldosteronism.	Spyroglou Ariadni
Oct 3rd	<b>P61-NAPACA</b>	Cardiovascular risk assessment in NAPACAs with co-existent PCOS: a joint ENS@T project	Spyroglou Ariadni
Oct 3rd	<b>P62-NAPACA</b>	Quantitation of 29 urinary steroids using Liquid Chromatography Tandem Mass Spectrometry	Bain Joshua



Oct 3rd	<b>P63-NAPACA</b>	Urinary steroidome investigation by dilute & shoot LC-MS analysis: a potential novel tool for characterizing adrenal tumors	Ponzetto Federico
Oct 3rd	<b>P64-NAPACA</b>	Cortisol levels after 1 mg dexamethasone suppression test are associated with increased intima-media thickness	Parazzoli Chiara
Oct 3rd	<b>P65-NAPACA</b>	Cardiometabolic comorbidities and cardiovascular events in “non-functioning” adrenal incidentalomas: a systematic review and meta-analysis	Parazzoli Chiara
Oct 3rd	<b>P66-NAPACA</b>	Associations of imaging phenotypes with clinical and biochemical characteristics in macronodular adrenal disease	Georgiadi Sofia
Oct 3rd	<b>P67-NAPACA</b>	Surgical outcome of Coagulation factors in Mild Autonomous Cortisol Secretion	Morelli Valentina
Oct 3rd	<b>P68-NAPACA</b>	Longitudinal Monitoring of Adrenal Steroid Excretion: Hair Analysis.	Fensome Grace
Oct 3rd	<b>P69-OTHER</b>	Undifferentiated retroperitoneal sarcoma mimicking an adrenal tumor.	Tkacz Edyta
Oct 3rd	<b>P70-OTHER</b>	Adrenal tumours in MEN1 patients – beyond the 3 P’s	Souteiro Pedro

## Poster (P) Presentation - Friday, 4<sup>th</sup> October 2024

Date	ID	Abstract Title	Author
Oct 4th	<b>P71-ACC</b>	Hierarchical clustering approach to diagnosing carcinoma of adrenal cortex	Mizera-Pietraszko Jolanta
Oct 4th	<b>P72-ACC</b>	Tumour board evaluation of exemplary paediatric ACC-patients in 8 international centres	Wiegering Verena
Oct 4th	<b>P73-ACC</b>	Mitotane kinetics and neuropsychological outcome in paediatric ACC patients on behalf of the ENSAT-PACT group	Wiegering Verena
Oct 4th	<b>P74-ACC</b>	Impact of a mutation in one of the genes of the mismatch repair (MMR) system on the clinical phenotype and response to treatment of metastatic adrenocortical cancer	Moog Sophie
Oct 4th	<b>P75-ACC</b>	Targeted molecular analysis in pediatric adrenocortical carcinoma for an improved personalized prognostication	Riedmeier Maria
Oct 4th	<b>P76-ACC</b>	Adrenal oncocyctic neoplasm of uncertain malignant potential-case study	Węgrzyn Karolina
Oct 4th	<b>P77-ACC</b>	Use of PLK1 and multiple CDKs inhibitors as a novel approach for the treatment of adrenocortical carcinomas	Esposito Emanuela
Oct 4th	<b>P78-ACC</b>	Adrenocortical tumors in pediatric population- diagnostic and therapeutic challenges from the perspective of one tertiary pediatric endocrine centre	Janus Dominika
Oct 4th	<b>P79-ACC</b>	Effect of manipulation of IR alternative splicing in adrenocortical carcinoma (ACC) cells	Catalano Rosa
Oct 4th	<b>P80-ACC</b>	Decreased expression of humanin during Adrenocortical carcinoma progression	Blatkiewicz Malgorzata
Oct 4th	<b>P81-ACC</b>	Extraordinary response to mitotane monotherapy in advanced aggressive adrenocortical carcinoma.	Aloini Maria Elena
Oct 4th	<b>P82-ACC</b>	Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines	Edholm Adam



Oct 4th	<b>P83-ACC</b>	A targetable antioxidant defense mechanism to EZH2 inhibitors enhances ACC vulnerability to ferroptosis	Nocito Marta Claudia
Oct 4th	<b>P84-ACC</b>	Aldosterone producing Adrenocortical Carcinoma: systematic review of existing literature.	Bulfone Luca
Oct 4th	<b>P85-ACC</b>	Steroids levels measured directly in adrenocortical tumors tissue reveal discrepancies with circulating levels, suggesting a fine regulation of steroids export	Bonnet-Serrano Fidéline
Oct 4th	<b>P86-ACC</b>	Understanding the Needs and Challenges of Patients with Adrenocortical Carcinoma: An Interdisciplinary Perspective	Roszkowska Zuzanna
Oct 4th	<b>P87-ACC</b>	SIAH1, a regulator of the Wnt/ $\beta$ -catenin pathway in adrenocortical cells	Puygrenier Pierre
Oct 4th	<b>P88-ACC</b>	The p16 promoter methylation rate validation in adrenocortical carcinoma	Božović Ana
Oct 4th	<b>P89-ACC</b>	Multi-tissue profiling of adrenocortical cancer-related miRNome and possible regulatory effects of long-term chronic or intermittent caloric restriction	Emen Merve
Oct 4th	<b>P90-ACC</b>	Diagnostic Work-up in Paediatric Adrenocortical Tumours – International Consensus through a DELPHI process	Idkowiak Jan
Oct 4th	<b>P91-ACC</b>	Cured Advanced Adrenocortical Carcinoma After Immunotherapy? A Case Report	Mollazadegan Kazhan
Oct 4th	<b>P92-ACC</b>	Hormonally active adrenocortical cancer in the course of MEN1 syndrome.	Kluczyński Łukasz
Oct 4th	<b>P93-ACC</b>	Advanced stage of adrenocortical carcinoma: therapeutic approach, pathological and biological findings	Cossa Alessandra
Oct 4th	<b>P94-ACC</b>	Exploring Surgical Frontiers: A Case Study of Advanced Adrenal Cortex Carcinoma with Inferior Vena Cava Involvement in a Young Patient.	Kłosowski Przemysław
Oct 4th	<b>P95-ACC</b>	Adrenocortical carcinoma with complete response to EDP-M	Falkman Lovisa
Oct 4th	<b>P96-ACC</b>	Targeted NGS Molecular Profiling and Its Clinical Application in Adrenocortical Cancer	Cioppi Francesca
Oct 4th	<b>P97-ACC</b>	Antioxidant defense in adrenocortical tumors: Down-regulation of NNT and lncRNA NNT-AS1 associates with poor prognosis	Bodoni Aline Faccioli
Oct 4th	<b>P98-ACC</b>	Bioinformatics analysis of the CDKN2A gene expression in adrenocortical carcinoma	Kožik Bojana
Oct 4th	<b>P99-ACC</b>	Modulability of stemness and secretory immune profile in adrenocortical cancer – insights from preclinical models	Luca Edlira
Oct 4th	<b>P100-ACC</b>	Mitotane Induces Non-Apoptotic Cell Death in Treatment Resistant Models of Adrenocortical Carcinoma	Feely Sarah
Oct 4th	<b>P101-ACC</b>	Adult and pediatric patients with adrenocortical carcinoma associated with the same germline oncogenic variant TP53 (p.R337H) and different outcome: The influence of somatic variants in ACC	Menezes Leandro
Oct 4th	<b>P102-ACC</b>	Constitutively active Wnt/beta-catenin signaling controls small extracellular vesicle biogenesis, composition and secretion in adrenocortical carcinoma	Bangoura Mohamed
Oct 4th	<b>P103-ACC</b>	Prognostic factors influencing survival in patients with metastatic adrenocortical cancer	Barac Nekić Anja
Oct 4th	<b>P104-ACC</b>	Targeting of CDK1/2/5/9 in Preclinical Models of Adrenocortical Carcinoma	Tamburello Mariangela
Oct 4th	<b>P105-PPGL</b>	Ectopic Cushing's syndrome from ACTH producing pheochromocytoma with paradoxal ACTH decrease after osilodrostat	Hána Václav



Oct 4th	<b>P106-PPGL</b>	Cardiac paragangliomas related to SDHD mutation	Thanasoula Foteini
Oct 4th	<b>P107-PPGL</b>	A study on incidence and related characteristics of PPGLs in a well-defined population	Giordano Imbroli Miriam
Oct 4th	<b>P108-PPGL</b>	3P Syndrome - Incidental Coexistence or casual relationship	Rzepka Ewelina
Oct 4th	<b>P109-PPGL</b>	Role of the tumoral micro environment in SDHx mutated Paraganglioma and Pheochromocytoma development	Sanceau Julie
Oct 4th	<b>P110-PPGL</b>	Novel germline TMEM127 mutation in a patient with pheochromocytoma and breast cancer	Jochmanova Ivana
Oct 4th	<b>P111-PPGL</b>	Pheochromocytoma-induced pseudo-Cushing syndrome	Bobrowicz Malgorzata
Oct 4th	<b>P112-PPGL</b>	Familial Paragangliomatosis with SDHD gene mutation	Tasouli Elisavet Charikleia
Oct 4th	<b>P113-PPGL</b>	A case of concurrent RET and FH gene mutations in a patient with metastatic pheochromocytoma	Siampano poulou Vasiliki
Oct 4th	<b>P114-PPGL</b>	Fifth postoperative day urinary metanephrine and normetanephrine levels as a marker for PPGLs surgery outcome	Vodanovic Ivana Dora
Oct 4th	<b>P115-PPGL</b>	False Positive Diagnosis Of Pheochromocytoma: A Retrospective Study From A Single Center	Zawadzka Karolina
Oct 4th	<b>P116-PPGL</b>	Comprehensive metabolite assessment in carriers of SDHx mutations	Lim Eugenie S.
Oct 4th	<b>P117-PPGL</b>	Unique Presentation of Pheochromocytoma in a Female Carrier of Germline X-linked ATRX Mutation: A Case Report	Tichomirowa Maria
Oct 4th	<b>P118-NAPACA</b>	An Artificial Intelligence-based Decision Support System for Classifying Patients with Adrenal Incidentalomas	Binas Dimitrios
Oct 4th	<b>P119-NAPACA</b>	Adrenal Tumors in the Albanian Population	Mitre Anila
Oct 4th	<b>P120-NAPACA</b>	Adrenal Tumor Pathologies	Mitre Anila
Oct 4th	<b>P121-NAPACA</b>	Bilateral adrenal oncocytic tumour of uncertain malignant potential in a patient with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.	Kurzyńska Anna
Oct 4th	<b>P122-NAPACA</b>	Robotic assisted adrenal surgery: recent advances	Yiannako poulou Eugenia
Oct 4th	<b>P123-NAPACA</b>	Adrenal sparing surgery and primary macronodular bilateral adrenal hyperplasia: Systematic Review	Yiannako poulou Eugenia
Oct 4th	<b>P124-NAPACA</b>	Adrenal incidentaloma and subclinical Cushing: minimally invasive adrenalectomy versus active surveillance	Yiannako poulou Eugenia
Oct 4th	<b>P125-NAPACA</b>	Plasma steroid profiling in patients with adrenal tumors – preliminary study	Szatko Alicja
Oct 4th	<b>P126-NAPACA</b>	Clinical and hormonal characterisation of a cohort of patients with bilateral macronodular adrenocortical disease (BMAD)	Nuta Andreea-Gabriela
Oct 4th	<b>P127-NAPACA</b>	Non-functioning adrenal tumors in relationship with the mineral metabolism, bone turnover markers and bone mineral density assessment amid the presence of diabetes mellitus	Manda Dana



Oct 4th	<b>P128-NAPACA</b>	The Origin of Myxoma in the Brain Parenchyma: Emboli vs. Metastasis	Weber Kuhn Aliny
Oct 4th	<b>P129-NAPACA</b>	Uncertainly pathogenic germline allelic variant of Armc5 in dogs with Bilateral Adrenal Lesions Associated with Cushing's Syndrome	De Marco Viviani
Oct 4th	<b>P130-NAPACA</b>	Clinical Characteristics of Patients with Classical Congenital Adrenal Hyperplasia: A Single Centre Experience	Mlekuš Kozamernik Katarina
Oct 4th	<b>P131-NAPACA</b>	Persistent Hypercortisolaemia in Cushing's syndrome: A Case Report	Htut Zin
Oct 4th	<b>P132-OTHER</b>	Innovative Approaches and Valorisation in Adrenal Gland Research: Pioneering Solutions for ACC, PCC/PGL, APA, and NAPACA	Zacharis Theo
Oct 4th	<b>P133-OTHER</b>	Clinical profile of patients with adrenal insufficiency admitted for hyponatremia	Borozan Sanja
Oct 4th	<b>P134-OTHER</b>	Impact of diagnosis and targeted interventions on the quality of life and cognition of patients with adrenal tumours: a systematic review	Prete Alessandro
Oct 4th	<b>P135-OTHER</b>	Primary Adrenal Angiosarcoma Presenting with life threatening hemorrhage.	Klosowski Przemyslaw
Oct 4th	<b>P136-OTHER</b>	Large tumors of adrenal glands diagnosed as metastases of burned-out germ cell tumor of the testis - a case report.	Tywanek Ewa
Oct 4th	<b>P137-OTHER</b>	Adrenalectomy improves direct metabolic consequences of mild autonomous cortisol secretion	Grethe Ueland